20 / 28
Pathology 2018
Research & Reviews: Journal of Medical and Health Sciences
ISSN: 2319-9865
Page 75
October 08-09, 2018
Edinburgh, Scotland
17
th
International Conference on
Pathology & Cancer
Epidemiology
T
he majority of lung cancer patients present with locally
advanced disease or with distant metastasis at the time of
diagnosis. Fine needle biopsy (FNA) is an important approach
for diagnosis and staging of lung cancer as well as for molecular
characterization of the tumor. The new 2015 edition of the WHO
classification and recommendations of IASLC (International
Association of Study of Lung Cancer) emphasize the importance
of accurate subclassification of lung cancers for targeted
therapy. Lung cancer is a heterogeneous group of neoplasms
and accurate diagnosis on small biopsies can be challenging.
Recent systematic reviews and meta-analyses have shown that
interobserver disagreement rates on the subclassification of
non–small cell lung cancer (NSCLC) are approximately 10-20% in
resected tumor specimens and 20-30% in small biopsy specimen
without immunohistochemical (IHC) stains. The morphological
heterogeneity of the lung cancer is also correlated with certain
molecular alterations. Therefore, it is necessary to introduce
newly updated guidelines of WHO and IASLC into our daily
practice to improve the accuracy of subclassification of NSCLC
for molecular profile and targeted therapy.
qli23@jhmi.eduMolecular signature and sub classification of lung cancers
using small biopsy samples – moving from targeted therapy to
immunotherapy
Qing Kay Li
Sidney Kimmel Comprehensive Cancer Center - Johns Hopkins University, USA
RRJMHS 2018
Volume: 7